The 36-month beta value for IMUX is at 1.36. Analysts have varying views on the stock, with 5 analysts rating it as a “buy”, 2 rating it as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for IMUX is 92.55M, and currently, shorts hold a 8.04% of that float. The average trading volume for IMUX on July 03, 2025 was 1.70M shares.
IMUX stock’s latest price update
The stock of Immunic Inc (NASDAQ: IMUX) has increased by 3.17% when compared to last closing price of $0.71.Despite this, the company has seen a gain of 3.55% in its stock price over the last five trading days. proactiveinvestors.com reported 2025-06-28 that Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company’s phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Proactive: Hello you’re watching Proactive, I’m joined by Immunic CEO Dr Daniel Vitt.
IMUX’s Market Performance
IMUX’s stock has risen by 3.55% in the past week, with a monthly rise of 0.71% and a quarterly drop of -33.73%. The volatility ratio for the week is 6.15% while the volatility levels for the last 30 days are 8.51% for Immunic Inc The simple moving average for the last 20 days is -3.54% for IMUX’s stock, with a simple moving average of -33.91% for the last 200 days.
Analysts’ Opinion of IMUX
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $10. The rating they have provided for IMUX stocks is “Buy” according to the report published on November 25th, 2024.
B. Riley Securities gave a rating of “Buy” to IMUX, setting the target price at $6 in the report published on August 27th of the previous year.
IMUX Trading at -17.28% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.14% of loss for the given period.
Volatility was left at 8.51%, however, over the last 30 days, the volatility rate increased by 6.15%, as shares sank -5.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.00% lower at present.
During the last 5 trading sessions, IMUX rose by +2.76%, which changed the moving average for the period of 200-days by -51.97% in comparison to the 20-day moving average, which settled at $0.7623. In addition, Immunic Inc saw -34.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMUX starting from Nash Duane, who purchase 20,000 shares at the price of $0.83 back on Jun 13 ’25. After this action, Nash Duane now owns 36,032 shares of Immunic Inc, valued at $16,694 using the latest closing price.
Tardio Jason, the President and COO of Immunic Inc, purchase 12,512 shares at $0.79 during a trade that took place back on Jun 05 ’25, which means that Tardio Jason is holding 12,512 shares at $9,884 based on the most recent closing price.
Stock Fundamentals for IMUX
The total capital return value is set at 19.89%. Equity return is now at value -246.26%, with -154.64% for asset returns.
Based on Immunic Inc (IMUX), the company’s capital structure generated -0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -393.2.
Currently, EBITDA for the company is -100.37 million with net debt to EBITDA at 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
In conclusion, Immunic Inc (IMUX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
